QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patients’ risk of developing cervical cancer.
POSITION TITLE: Chief Executive Officer
REPORTING TO: Board of Directors
THE COMPANY: TEDCO (Maryland Technology Development Corporation)
“The economic contribution to the Maryland economy of TEDCO’s five core research, technology transfer, and commercialization programs totaled almost $1 billion in 2015, generating a total of 4,358 jobs” – Battelle Technology Partnership Practice, Report on Economic Impacts of TEDCO
TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology-based businesses in all regions of the State. TEDCO is an independent organization that strives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of start-up companies in Maryland’s innovation economy. In Maryland and beyond, TEDCO is a resource of mentoring, funding and networking for entrepreneurs and start-ups that need guidance as they bring innovative concepts to market. TEDCO is more than an early stage funding resource. It is the hub of Maryland’s entrepreneurial network where start-ups find mentors, organizational assistance, facilities for daily operations, and a roadmap for success.
Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome testing products and services, today announced that co-founders Luis Diaz, MD, and Victor Velculescu, MD, PhD, have won the EY Entrepreneur Of The Year® 2016 Award in the Maryland region.
Emergent BioSolutions Inc. is a global specialty pharmaceutical company, which offers specialized products to governments and healthcare providers. The company derives most of its revenue from one product, BioThrax, which is the only FDA-licensed vaccine for the prevention of anthrax disease. In 2015, about 56% of the company’s revenue came from the sale of BioThrax with the remainder coming from the sale of their other biodefense products, biosciences products, and contract manufacturing.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent’s supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55, the company’s large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
As cities continue to invest more in smart city technologies, questions surrounding how to staff those moves can puzzle city leaders.
Martin O’Malley, the former mayor of Baltimore and governor of Maryland, suggested during remarks at the Smart Cities Innovation Summit that during his leadership — both at the city and state levels — having a chief innovation officer close to the executive was key to driving government away from the status quo and into new possibilities.
Alexandria Real Estate Equities, the owner and developer of the Alexandria Center for Life Science on the East Side of Manhattan, has just launched an incubator space for biotech start-ups.
The new life science laboratory and office platform, which will be called Alexandria Launchlabs, promises 15,000 s/f of space that provides “the necessary resources and collaborative environment to start transforming novel ideas into innovative, early-stage companies that develop products to improve human health.”
Join us for a thrilling evening of start-up pitches from multiple sectors in healthcare including: Services, Health IT, Biotechnology, Medical Devices and Diagnostics. Applications are still being accepted, so if you not afraid of getting nipped by one of our judges, send your information to jhausfeld@sopenet.org.
The approval of Professor Patrick O’Shea’s selection by UCC’s governing body is the first external appointment to the role in 50 years.
Most of his academic career has been at University of Maryland and elsewhere in the US, but he stays in touch with the Irish higher education system. The UCC physics graduate is a director of the Wild Geese Network of Irish Scientists, and he hosted University College Dublin president Andrew Deeks earlier this year.
We were pleased to see the interest in our recent blog on the unique number of investigators applying for and receiving NIH research project grants (RPGs). Some of you (through the blog page or through other media) have asked about whether we have similar data for our Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program. We have generated analogous figures for SBIR and STTR grants, and today’s post shares this investigation of the question, “How many unique researchers are seeking SBIR/STTR funding?”
Funding and Research OpportunitiesThe following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
- Form Correction Made for All NIH Fellowship Opportunities
- (NOT-OD-16-106) National Institutes of Health
- National Institute on Deafness and Other Communication Disorders, National Institute of General Medical Sciences
- Notice of NHLBI Participation in PA-16-305 “Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship for Students at Institutions With NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)”
- Notice of NHLBI Participation in PA-16-306 “Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)”
Program Announcements:
- Administrative Supplements for Research on Dietary Supplements (Admin Supp)
- (PA-16-319)
- Office of Dietary Supplements, John E. Fogarty International Center, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute
The venture fund working to make sweetgreen and CustomInk into household names has raised more than half a billion dollars to double down on its strategy.
Rep. Steny Hoyer and other Democratic lawmakers plan to outline a broad strategy for expanding U.S. manufacturing in Baltimore on Monday, at a time when Washington has stalled on measures sought by the industry.
Merck has added a month-long Silicon Valley stay to the pot on offer for start-ups participating in the next round of its accelerator programmes in Germany and Kenya. The programmes seek to support healthcare, life science and performance materials start-ups, with a particular focus on those developing digital solutions.
The Pentagon has made an unprecedented push to cozy up with Silicon Valley over the past two years, opening satellite offices on the West Coast and Boston in an effort to import fresh insight, ideas and innovation from the private sector to the military.
Global epidemics are outrunning globally accessible containment and cures. There are now more ways to spread diseases worldwide than safe, effective ways to counter them. Biomedical stakeholders are engaged in finding solutions. Now rumored recommendations pending at a UN High Level Panel may make matters worse. Appointed by outgoing Secretary General Ban Ki-Moon, the Panel is said to be preparing to release its examination of world “Access to Medicines”. Amazingly it is rumored to be encouraging international flouting of U.S. Bayh-Dole-based patent protection and producer pricing prerogatives. This inevitably will undermine our nation’s life science innovation ecosystem, effectively destroying world hopes for effective response to evolving epidemics.
The UK biotechnology sector continues to build on the success of previous years, raising an unprecedented £900m on the London Stock Exchange in 2015 and recording the highest level of venture finance in recent years, according to the latest report Money, momentum and maturity: UK biotech financing and deals in 2015/16 compiled by the UK BioIndustry Association (BIA) in partnership with Evaluate and the London Stock Exchange.
Imagine the workplace during flu season. Some people get sick and display clear symptoms—a warning sign to coworkers to avoid contact and for that individual to stay home. Others are infected, but never or only belatedly exhibit the tell-tale signs of sickness, meaning they can infect coworkers without knowing it. If healthcare professionals had the ability to test in advance whether a person is likely to spread a disease following infection, they could recommend specific measures to treat the person or limit exposure and perhaps keep an outbreak from growing into an epidemic or pandemic.
When David R. Tabatadze’s small biotechnology venture ran out of money in 2013, he almost gave up on it.
He went to pharmaceutical companies and “angel” investors, those individuals willing to put modest amounts of money into new businesses. None were interested in funding his research into potential genetic medicines.
